期刊文献+

TNF-α、IL-6在炎症性肠病发病机制中的研究进展 被引量:32

Research Progress of Tumor Necrosis Factor Alpha and Interleukin-6 in the Pathogenesis of Inflammatory Bowel Disease
在线阅读 下载PDF
导出
摘要 炎症性肠病是一类病因不明的胃肠道慢性非特异性炎症,其发病过程是包括多种细胞因子在内的自身免疫的异常,最终导致组织的损伤,属于自身免疫性疾病的一种,其中肠道免疫系统调节异常在其发病机制中起着极其重要的作用,而作为重要的促炎因子和免疫调节因子肿瘤坏死因子α(TNF-α)、白细胞介素6(IL-6)在炎症性肠病的发病过程中参与炎症的发生以及信号的转导。该文就近年来TNF-α、IL-6在炎症性肠病发病机制中的研究予以综述。 Inflammatory bowel disease is a kind of unknown etiology of chronic nonspeeific inflammation of the gastrointestinal tract, the onset process of which includes a variety of cytokines immune abnormalities, eventually leading to the tissue damage;it is a kind of autoimmune disease,and the intestinal immune system dysregulation plays an extremely important role in the pathogenesis; tumor necrosis factor alpha and interleu- kin-6, as proinflammatory factors and immune adjustment factors are involved in inflammation and signal transduction in the pathogenesis of inflammatory bowel disease. Here is to make a review of the tumor necrosis factor alpha and interleukin-6 role in the pathogenesis of inflammatory bowel diseases.
出处 《医学综述》 2014年第7期1174-1176,共3页 Medical Recapitulate
关键词 肿瘤坏死因子Α 白细胞介素6 炎性肠病 Tumor necrosis factor alpha Interleukin-6 Inflammatory bowel diseases
  • 相关文献

参考文献20

  • 1纪桂贤,王邦茂.细胞因子与炎症性肠病关系研究新进展[J].天津医科大学学报,2004,10(S1):51-54. 被引量:5
  • 2张子其,刘婧.肿瘤坏死因子与炎症性肠病[J].中国实用内科杂志,2007,27(18):1439-1442. 被引量:6
  • 3Parameswaran N, Patial S. Tumor necrosis factor-a signaling inmacrophages[J]. Crit Rev Eukaryot Expr,2010,20(2) :87-103.
  • 4Paul AT,Gohil VM,Bhutani KK. Modulating TNF-alpha signalingwith natural products[J]. Drug Discov Today,2006,11( 15/16):725-732.
  • 5Ctinther C,Martini E,Wittkopf N,et al. Caspase-8 regulates TNF-a-induced epithelial and terminal ileitis [J]. Nature, 2011, 477(7364) :335-339.
  • 6Ishiguro Y. Mucosal proinflammatoiy cytokine production correlateswith endoscopic of ulcerative colitis [J]. J Gastroenterol, 1999,34(1):66-74.
  • 7Goh K,Xiao SD. Inflammatory bowel disease:a survey of the epide-miololgy in Asia[J]. J Dig Dis,2009,10(1) :1~6.
  • 8Murch SH,Braegger CP,Walker-Smith JA,et al. Location of tumornecrosis factor alpha by immunohistochemistry in chronic inflam-matory bowel disease[J]. Gut, 1993,34( 12) :1705-1709.
  • 9Olsen T,Goll R,Cui G,et al. Tissue levels of tumor necrosis factor-alpha correlates with grade of inflammation in untreated ulcerativecolitisf J]. Scand J Gastroenterol,2007,42( 11) :1312-1320.
  • 10Haddatz D, Bockemtihl M, Ramadori G. Quantitative measurementof cytokine mRNA in inflammatory bowel disease: relation to clini-cal and endoscopic activity and outcome [J]. Eur J GastroenterolHepatol,2005,1 (7) :547-557.

二级参考文献24

  • 1宋瑛,吴开春,张沥,郝志明,李红涛,张玲霞,乔泰东,李彩宁,樊代明.肿瘤坏死因子基因多态性与炎症性肠病的相关性分析[J].中华消化杂志,2005,25(4):202-206. 被引量:11
  • 2Fantini MC Pallone F. Cytokines: from gut inflammation to colorectal cancer. Curr Drug Targets 2008; 9: 375-380.
  • 3Gionchetti P, D'Arienzo A, Rizzello F, Manguso F, Maieron R, Lecis PE, Valpiani D, Iaquinto G, Annese V, Balzano A, Varoli G, Campieri M. Topical treatment of distal active ulcerative colitis with beclomethasone dipropionate or mesalamine: a single-blind randomized controlled trial. J Clin Gastroenterol 2005; 39: 291-297.
  • 4Chow DK, Leong RW, Tsoi KK, Ng SS, Leung WK, Wu JC, Wong VW, Chan FK, Sung JJ. Long-term follow-up of ulcerative colitis in the Chinese population. Am J Gastroenterol2009; 104: 647-654.
  • 5Sventoraityte J, Zvirbliene A, Kiudelis G, Zalinkevicius R, Zvirbliene A, Praskevicius A, Kupcinskas L, Tamosiunas V. Immune system alterations in patients with inflammatory bowel disease during remission. Medicina(Kaunas) 2008; 44: 27-33.
  • 6Senn JJ, Klover PJ, Nowak lA, Zimmers TA, Koniaris LG, Furlanetto RW, Mooney RA. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Bioi Chem 2003; 278: 13740-13746.
  • 7Dimitriou ID, Clemenza L, Scotter AI, Chen G, Guerra FM, Rottapel R. Putting out the fire: coordinated suppression of the innate and adaptive immune systems by SOCS1 and SOCS3 proteins. Immunol Rev 2008; 224: 265-283.
  • 8Li Y, Chu N, Rostami A, Zhang GX. Dendritic cells transduced with SOCS-3 exhibit a tolerogenic/DC2 phenotype that directs type 2 Th cell differentiation in vitro and in vivo. J Immunol2006; 177: 1679-1688.
  • 9El Kasmi KC Holst J, Coffre M, Mielke L, de Pauw A, Lhocine N, Smith AM, Rutschman R, Kaushal D, Shen Y, Suda T, Donnelly RP, Myers MG, Alexander W, VignaJi DA, Watowich SS, Ernst M, Hilton DJ, Murray PJ. General nature of the STAT3- activated anti-inflammatory response. J Immunol 2006;177:7880-7888.
  • 10Berlato C, Cassatella MA, Kinjyo I, Gatto L, Yoshimura A, Bazzoni F. Involvement of suppressor of cytokine signaling-3 as a mediator of the inhibitory effects of IL-10 on lipopolysaccharide-induced macrophage activation. J Immunol 2002; 168: 6404-6411.

共引文献37

同被引文献406

引证文献32

二级引证文献190

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部